Drug Approval | September 12, 2021
US FDA grants Soligenix Orphan Drug Designation for the treatment of T-cell lymphoma
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
According to WHO, over 1.5 million people died of TB in 2020
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Subscribe To Our Newsletter & Stay Updated
